This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD19 CAR-T therapy for patients with refractory myasthenia gravis, and to evaluate the pharmacokinetics of CD19 CAR-T in patients.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Dose-limiting toxicity (DLT)
Timeframe: Baseline up to 28 days after CD19 CAR T-cells infusion
Incidence of treatment-emergent adverse events (TEAEs)
Timeframe: Up to 90 days after CD19 CAR T-cells infusion
Maximum tolerable dose
Timeframe: From date of initial treatment to Day 28 post CD19 CAR-T infusion.